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The advancement of cancer immunotherapy faces barriers which limit its eﬃcacy. These include weak immunogenicity of the
tumor, as well as immunosuppressive mechanisms which prevent eﬀective antitumor immune responses. Recent studies suggest
that aberrant expression of cancer testis antigens (CTAs) can generate robust antitumor immune responses, which implicates
CTAs as potential targets for immunotherapy. However, the heterogeneity of tumor cells in the presence and quantity of CTA
expression results in tumor escape fromCTA-specific immune responses. Thus, the ability tomodulate the tumor cell epigenome to
homogenously induce expression of such antigens will likely render the tumor more immunogenic. Additionally, emerging studies
suggest that suppression of antitumor immune responses may be overcome by reprogramming innate and adaptive immune cells.
Therefore, this paper discusses recent studies which address barriers to successful cancer immunotherapy and proposes a strategy
of modulation of tumor-immune cell crosstalk to improve responses in carcinoma patients.
1. Introduction
Conventional approaches in the therapy of cancer, such as
chemotherapy, have shown only modest success in the treat-
ment of advanced carcinoma [1]. Historical comparisons
since the late 1970s have shown that the introduction of
combination cytotoxic chemotherapy has produced amodest
9–12 month gain in survival compared with untreated
breast cancer patients [2]. Despite advances in conventional
cytotoxic therapies of early-stage breast cancer [3, 4] there
remains no therapeutic strategy that can ensure relapse-
free survival. Furthermore, studies have shown that 20%
of clinically disease-free early-stage breast cancer patients
relapse within 10 years after conventional therapies [5];
indeed, most cancer-related deaths within the United States
are attributed to relapse [6]. Thus, there is an urgent
need to develop more eﬀective therapies to overcome
breast cancer relapse and to treat advanced cancer. To
this end, immunotherapy emerges as promising strategy
for the prevention of tumor relapse, when combined with
conventional therapies.
Thus far advances in the immunotherapy of cancer have
also been met with a number of setbacks. Several vaccination
strategies used against breast cancer have been successfully
employed to induce tumor-specific CD8+ and CD4+ T-
cell responses; however, such immunological responses have
rarely been potent enough to achieve objective results
[7–9]. Additionally, it has been demonstrated by several
groups that adoptive cellular therapy (ACT) directed against
highly immunogenic melanoma-associated antigens results
in objective responses in animal models as well as in some
melanoma patients [10, 11]. ACT has also been tested against
breast cancer both in preclinical and clinical studies [12,
13]; however, unlike melanoma, ACT has not produced
promising results in breast cancer patients and has only dis-
played eﬀectiveness in animal models in prophylactic settings
[14, 15], rather than against well-established, vascularized
tumors. Such failure has been attributed, in part, to (i) the
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lack of a robust antitumor immune response as a result of the
expression of weakly immunogenic tumor antigens coupled
with the presence of low frequency and low aﬃnity T cells
and (ii) the suppression of antitumor immune responses
though the activity of immunosuppressive mechanisms.
Indeed, distant recurrence of breast cancer may occur
even in the presence of tumor-specific immune responses.
The ability to overcome these barriers will likely improve
the eﬃcacy of immunotherapy directed against cancer. To
address these issues, the crosstalk between tumor cells and
cells of the immune system should be altered in order for
reprogrammed tumor cells and immune cells to prevent
tumor relapse as well as induce regression of advanced
cancer.
2. Immune Suppression
It is now well established that the mammalian immune
response can be suppressed through various mechanisms.
The expression of immunoregulatory molecules, such as
CTLA-4 and PD-1 as well as the ectoenzyme, CD73,
inhibits the proliferation and function of conventional T
cells [16, 17]. Furthermore, immunosuppressive cells such
as alternatively activated M2 macrophages, type II NK cells,
and regulatory T cells have been demonstrated to antagonize
tumor immunosurveillance [18–22].
Results from clinical studies involving breast cancer
patients indicate that another critical regulator of tumor
immunosurveillance, the myeloid-derived suppressor cell
(MDSC), was found to be the most abundant type of
suppressor cell [23, 24] and thus represent a major hurdle in
overcoming antitumor immune suppression. MDSCs repre-
sent a phenotypically heterogeneous population of myeloid
cells at diﬀerent stages of maturation. These cells have been
found in tumor-bearing mice as well as cancer patients and
have been shown to possess multiple mechanisms to suppress
the antitumor immune response [25, 26]. Such responses
include disrupting TCR antigen recognition and T-cell
mediated IFN-γ production [27, 28], depletion of essential
amino acids within the tumor microenvironment [29],
and overproduction of reactive oxygen species (ROS) [30].
MurineMDSCs are defined as coexpressing Gr-1 and CD11b,
with two subsets commonly being described: granulo-
cytic (CD11b+Ly-6G+Ly-6Clow) and monocytic (CD11b+Ly-
6G−Ly-6Chigh) [31]. Human MDSCs, on the other hand,
have been diﬃcult to be identified as initial studies revealed
that these cells express varied phenotypes and suppressive
patterns [25]. It is now regarded, however, that human
MDSCs fall into two main subsets: a monocytic population
characterized by expression of CD14 and a granulocytic
population characterized by CD15 expression; both subtypes
have been reported to express the common myeloid markers
CD11b and CD33, with minimal expression of myeloid mat-
uration markers such as HLA-DR [32]. The accumulation
of these cells in association with cancer development is
corroborated by experimental mouse models, indicating that
MDSCs develop as a function of tumor progression [33]. For
instance, our group has previously reported that FVBN202
mice, which overexpress the rat neu oncogene in their mam-
mary glands, develop atypical ductal hyperplasia (ADH) and
ductal carcinoma in situ (DCIS) in mammary epithelial cells
prior to the formation of spontaneous mammary tumors
[34]. DCIS of the breast is conventionally regarded as a
precursor of invasive breast cancer, and ADH is a risk factor
for the development of the disease [35, 36]. Compromised
antineu immune responses occur as a result of the emergence
of premalignant events, such as ADH and DCIS, which are
characterized by an accumulation of MDSCs in the blood,
bonemarrow, secondary lymphoid tissues, and within tumor
lesions due to an increased production of tumor-derived
soluble factors [34, 37–41]. Such findings provide evidence
that MDSCs function as potent inhibitors of antitumor
immunity in breast cancer models. Likewise, human MDSCs
have been observed to negatively regulate both adaptive and
innate immunity during cancer development and progres-
sion, with accumulation having been observed in peripheral
blood and lymphoid tissues as well as draining tumor
sites of cancer-bearing patients [31]. In addition to breast
cancer, the accumulation of MDSCs has been observed in
other neoplastic diseases, such as hepatocellular, pancreatic,
esophageal, and colorectal cancers [26], and is generally
correlated with advanced clinical cancer stage and metastatic
tumor burden with a demonstrated suppression of anti-
tumor immune responses correlating with poor responses
following conventional therapies [14, 23, 42, 43]. Thus,
MDSC accumulation is paramount in the ability of cancer to
evade eﬀective immune responses. Therefore, suppression of
immune responses mediated by MDSCs must be overcome
to rescue and facilitate eﬀective tumor-specific immunity.
Accordingly, it was reported that activated NKT cells can
overcome MDSCs, thereby supporting an eﬀective adaptive
immune response against cancer [15, 44, 45]. Our group
has recently developed a novel strategy of reprogramming
immune cells ex vivo to overcome MDSC-mediated antitu-
mor immune suppression in a prophylactic model of murine
breast carcinoma upon adoptive transfer, which resulted in a
demonstrated ability to enhance immune mediated rejection
of tumors [15]. However, this approach failed to protect mice
in a therapeutic model against established tumors. Thus,
in addition to overcoming MDSC-mediated suppression,
improvements in the eﬃcacy of immunotherapy likely will
require further addressing the crosstalk between immune
and tumor cells; one such strategy is enhancing tumor cell
immunogenicity.
3. In Situ Vaccination: Modulating the Tumor
Cell Epigenome
A barrier for successful immunotherapy of breast cancer is
the low immunogenicity of tumor cells, for example, expres-
sion of tumor associated antigens which are recognized as
“self” by the immune system. Therefore, improving the
immunogenicity of tumor is essential to improving tumor
immunotherapy. To this end, in situ induction of foreign-like
antigens, such as cancer testis antigens (CTA), to which T-
cell tolerance does not exist, is a promising option. CTAs are
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highly immunogenic with no natural self-tolerance due to
the observation that they are normally only expressed during
embryonic development; after birth, expression is generally
limited to immunologically privileged germ cells and the
placenta [46]. Aberrant CTA expression was first described
in melanoma; as such, this expression was found to generate
CTA-specific cytotoxic T-cell responses [47]. Recently, it
was reported that treatment of metastatic melanoma with
autologous CD4+ T cells specific for the CTA, NY-ESO-
1, elicited long-term complete remission [48]. In addition
to melanoma, CTA expression has also been observed in
hematological malignancies [49] as well as solid tumors,
including breast cancer [50, 51]. Further, CTA expression
in breast cancer has been shown to elicit a broad range of
cellular and humoral immune responses [50, 52, 53]; both
CD8+ T cell and CD79+ B cell infiltration has been observed
in primary and metastatic NY-ESO-1 expressing breast
cancer [54]. Of note, a significantly elevated expression
of NY-ESO-1 and MAGE-A, another highly immunogenic
CTA, was detected in triple negative breast cancers compared
to other types of breast cancer [55], which therefore represent
antigenic targets in an otherwise immunologically refractory
breast cancer subtype.
Importantly, CTA expression is normally silenced by
methylation within the promoter region of these genes.
Methylation at the C-5 position of cytosine bases within
DNA is a covalent chemical modification which characterizes
a key, biologically functional, epigenetic modification of the
animal genome [56]. This action primarily occurs at CpG
dinucleotides in mammals, where DNA-methyltransferases
(DNMTs) mediate the transfer of methyl groups to cytosine,
thereby generating 5-methylcytosine (5mC) that has been
shown to play a critical role in the cellular protein expres-
sion by transcriptional silencing of genes [57]. Aberrant
CTA expression likely occurs due to epigenetic molecular
alterations which arise during tumor progression; cancer
cells display drastic changes in DNA methylation status,
typically exhibiting global DNA hypomethylation as well as
region-specific hypermethylation [58], resulting in irregular
expression of CTAs. Our group has observed that a lack of
such aberrant CTA expression within breast tumor lesions at
the time of diagnosis correlated with eventual relapse after
conventional therapies (unpublished data) along with the
lack of expression of an immune function gene signature
[59]. Conversely, the tumors in patients who remained free of
relapse expressed both CTAs and the immune function gene
signature. These data suggest that CTA expression in breast
cancer patients activates eﬀective immune responses which
results in improved prognosis after conventional treatments.
In order to induce and/or increase expression of CTAs
to function as target antigens and improve the prognosis in
patients with breast cancer, it is possible to modulate the
tumor epigenome to initiate the cellular CTA transcriptional
program; such an approach will serve to impart a more
immunogenic tumor cell phenotype. Azacitidine (Aza) and
Decitabine (Dec) are both hypomethylating agents employed
in epigenetic therapy tomodify cellularmethylation patterns;
both of these agents have been approved for clinical use
in the treatment of myelodysplastic syndrome. Aza and
Dec function as cytosine analogs, which lead to their
incorporation into newly synthesized DNA strands during
S phase of the cell cycle; these agents have been shown
to induce and/or increase the expression of various CTAs
in a variety of in vitro and in vivo tumor models [49,
52–54]. Both Aza and Dec have demonstrated the ability
to induce the expression of CTAs, as well as the tumor
suppressor gene p53 [60] and the death receptor Fas [61]
on tumor cells. These are attributed to their capacity to
function as potent DNMT inhibitors through the formation
of a covalent complex with a serine residue at the active
site of DNMT1, which therefore results in CpG island
demethylation during cellular proliferation. This, in turn,
results in hypomethylation within the promoter of tumor
suppressor genes as well as a highly immunogenic CTAs [56,
62–64], thereby rendering tumor cells susceptible to CTA-
reactive immune responses and suppression of proliferation
via expression of p53, as well as rendering these tumor cells
more susceptible to Fas L-induced apoptosis by CTA-reactive
T cells. Such modulation of CTA expression using Aza has
been shown to generate CTA-specific T-cell responses in
patients with acute myeloid leukemia, as demonstrated by
our group [65]. Others have demonstrated the feasibility to
induce CTA expression in vivo using Dec in the 4T1 model
of murine breast carcinoma, resulting in greater tumor cell
cytotoxicity upon treatment with CTA-specific T cells [56].
Further, an ongoing clinical trial in breast cancer patients is
testing the eﬃcacy of Dec for the induction of the expression
of ER/PR in patients with hormone receptor negative tumors
in order to render them susceptible to hormonal therapy
[66].
Decitabine is a particularly attractive option to induce
CTA expression as it functions as a prodrug which requires
activation by deoxycytidine kinase (DCK), an enzyme prefer-
entially expressed in tumor cells and myeloid cells. Thus, the
eﬀects of Dec are likely tissue specific, as DCK is selectively
expressed in tumor cells and myeloid cells, thus protecting
T and B cells from the potentially deleterious demethylating
eﬀects of this agent. In addition, DCK has been found
to be overexpressed in poor outcome breast cancer [67],
suggesting that epigenetic therapy to induce CTA expression
may prove to be an eﬃcacious approach in breast cancer
patients with poor prognosis.
Our group has recently demonstrated that epigenetic
modulation using sequential Aza and the immunomodula-
tory agent lenalidomide for the induction of CTA expression
in the tumor and CTA-specific antitumor immune responses
in patients withmultiple myeloma [65]. Upon determination
of CTA expression in bone marrow of multiple myeloma
patients following treatment with Aza, we found that CTA
expression is induced exclusively in CD138+ malignant
plasma cells in vivo, which suggests a preferential induction
of hypomethylation in CTA promoters within tumor cells.
As a result of such a strategy, which we term in situ
vaccination or epigenetic induction of an adaptive immune
response, we have determined that the observed induction
of CTA expression resulted in the generation of robust CTA-
specific adaptive immune responses [65]. We believe that
this strategy will maintain long-term surveillance against
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malignant plasma cells in patients with MM and translate
into prolonged freedom from progression in this otherwise
incurable disease. Furthermore, these data suggest that
epigenetic therapeutic agents, such as Dec, when used
in a neoadjuvant setting, may induce CTA expression in
tumor-bearing patients and may therefore activate early
CTA-specific immune responses to prevent recurrence after
conventional therapies.
4. Reprogramming of Tumor-Sensitized
Immune Cells
The rationale for ex vivo reprogramming of tumor-sensitized
immune cells is based on overcoming the low frequency of
endogenous tumor-reactive T cells by driving their expan-
sion and activation toward the most eﬀective antitumor
phenotype(s). We have previously shown the ability of
ex vivo reprogrammed Her2/neu sensitized immune cells
to protect mice in a prophylactic setting when used in
an adoptive cellular therapy (ACT) setting [15]. Cellular
reprogramming through the combined use of bryostatin 1,
a potent activator of classical and novel protein kinase C
(PKC) [68, 69], and ionomycin (B/I), a calcium ionophore
[70, 71], followed by diﬀerentiation using gamma-chain (γ-
c) cytokines (IL-2, IL-7, and IL-15) results in the ability
to selectively activate tumor-primed T cells, NK cells, and
NKT cells, as described by our group [72, 73]. In particular,
the generation of both CD4+ and CD8+ central memory
(CD44+ CD62Lhigh) lymphocytes, which are necessary to
mediate protection in ACT recipients upon challenge with
antigen expressing tumor cells, is observed. Furthermore,
we observed that reprogrammed NK/NKT cells surprisingly
functioned to render T cells resistant to MDSC suppression
and induced tumor rejection even in the presence of MDSC
in FVBN202 mice [15].
Therefore, it may prove beneficial to harvest autologous
peripheral blood mononuclear cells (PBMC) from breast
cancer patients having received neoadjuvant Dec treatment
in order to reprogram CTA-sensitized immune cells using
B/I and γ-c cytokines; following conventional therapies,
such reprogrammed lymphocytes can then be reinfused
back into the host, whereupon they may exert long-lived
protection against relapse, even in the presence of classical
immunosuppressive cells such as MDSCs.
5. Rescue of Late Antitumor
Immune Responses
We have previously demonstrated that MDSC accumulation
results as a function of tumor-derived soluble factors, such
as GM-CSF, in the FVBN202 model of breast carcinoma
[74], while others have identified additional tumor-derived
soluble factors and inflammatory cytokines which are
responsible for the accumulation of MDSCs [38–41]. We
have also verified the ability of radiation therapy (RT) to
reject primary tumors, thereby resulting in the reduction
of MDSCs within the tumor bearing host [15]. Ionizing
irradiation is known to cause cellular stress and enhance
the synthesis of a variety of immune-stimulatory and -
modulating molecules such as heat shock proteins (HSP)
[75, 76], high mobility group box 1 (HMGB1) [76], and
NKG2D ligands [77]. Such danger signals are then sensed by
cells of the immune system. For instance, toll-like receptor
(TLR)-4 on DCs interacts with its ligands including HMGB1
[78] and HSPs [79] and enhances maturation and antigen
presentation capacity of DCs. Detection of danger signals in
tissues by leukocytes activates an immune response involving
cells of the innate (myeloid and NK cells) and adaptive
(T and B cell) lineages. RT-induced NKG2D ligand, an
activating receptor for NK cells, and HSP70 render tumor
cells more susceptible to NK-cell-mediated cytolysis [80].
Thus, combining RT with an enhanced immunotherapeutic
strategy, such as neoadjuvant administration of Dec, is
likely to enhance antitumor immune responses and produce
objective responses against advanced breast cancer and result
in a decreased risk of disease relapse. The removal of MDSC-
mediated suppression via RT may, therefore, facilitate the
rescue of CTA-specific antitumor immune responses against
residual tumor cells and result in the prevention of future dis-
ease recurrence. Accordingly, we propose that CTA-reactive
T cells became antigen experienced during tumorigenesis
due to aberrant CTA expression; however, it is likely that
such CTA expression occurs late in the progression of the
tumor, thus rendering CTA-reactive T cells ineﬀective due to
MDSC accumulation via tumor-derived soluble factors. It is
expected, nevertheless, that patients who receive neoadjuvant
Dec followed by radiation therapy or surgery to remove
the primary tumor will experience a reduction in MDSC
accumulation; we propose that such activity will result in the
rescue of CTA-reactive T cells from suppression to eliminate
residual tumor cells in order to decrease the likelihood of
future disease recurrence.
6. Limitations and Future Considerations
The majority of solid tumors and hematological malignan-
cies undergo a period of dormancy that is characterized by
years to decades of minimal residual disease (MRD) in which
cancer progression has paused [81, 82]. Indeed, disease-
free periods in breast cancer patients can last as long as 25
years and are clearly associated with the presence of MRD;
subsequent relapse represents the escape of the tumor from
dormancy, which can include locoregional recurrence as well
as distant metastatic disease [81, 83, 84]. Tumor dormancy
may be the result of hypoxic stress, as well as other as
yet unknown cues from the microenvironment of the host
[85]. The mechanism of tumor cell dormancy may best be
explained by cellular quiescence. Quiescence is defined as
growth/proliferation arrest and is thought to be due to G0-
G1 cell cycle arrest, during which cells pause cellular activities
which can render them refractory to diﬀerentiation and
proliferation [86, 87]. Thus, given that DNMT inhibitors Dec
and Aza are incorporated into cellular DNA during S phase,
the induction of CTA expression requires tumor cells to be
actively proliferating. As such, the in situ vaccination strategy
outlined above will likely be less eﬀective against any residual
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tumor cells that have entered G0-G1 arrest. Therefore,
further understanding the process by which residual tumor
cells naturally exit dormancy may provide novel approaches
to coax such cells to exit cell-cycle arrest. Future studies
investigating the ability of Aza or Dec combined with histone
deacetylase inhibitors (HDI) to reinitiate the cell cycle would
be beneficial in addressing this problem. Such eﬀorts may
result in an enhanced ability of in situ vaccination strategy
to target and eliminate MRD, which may therefore lower the
incidence of tumor recurrence presently observed in breast
cancer patients.
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